CD274 and neoplasm: Patients can now be evaluated for immunotherapy‐related indicators, including PD‐L1, TMB and MSI, before immunotherapy is administered, both to exclude patients with tumours that may benefit less and to analyse some biomarkers that can predict the efficacy of immunotherapy drugs.39, 41, 42, 43